A major breakthrough in lung cancer treatment has been achieved with subcutaneous toripalimab, showing promising results in nonsquamous NSCLC patients. But here's where it gets controversial: Can a simpler, more convenient injection method really match the efficacy of traditional intravenous therapies? And this is the part most people miss — the impact this could have on patients' daily lives.
Junshi Biosciences recently announced that their subcutaneous form of toripalimab (JS001sc) combined with chemotherapy has successfully reached the primary endpoints in a phase 3 trial for first-line treatment of metastatic or recurrent nonsquamous non–small cell lung cancer (NSCLC). This pivotal JS001sc-002-III-NSCLC study (NCT06505837) demonstrated that the drug’s subcutaneous administration achieves drug exposure levels that are not inferior to the conventional intravenous toripalimab (JS001), providing a potentially more patient-friendly option.
The company reported that safety and efficacy profiles were comparable between the intravenous and subcutaneous formulations. They plan to showcase the full study data at a major international conference soon and intend to submit a new drug application to regulatory bodies to approve JS001sc for the same indications already authorized for JS001.
Jianjun Zou, MD, CEO of Junshi Biosciences, emphasized the significance of this advancement by recalling toripalimab's journey as China’s first domestically developed PD-1 antibody, which currently has approvals across 12 different medical indications, helping countless patients. Dr. Zou pointed out a real-world challenge unearthed during clinical use: patients receiving immunotherapy, either alone or alongside other treatments, often suffer from the burden of frequent intravenous catheter use and prolonged infusion times. The success of the phase 3 trial for the subcutaneous version represents a crucial step not just in maintaining drug effectiveness but also in enhancing treatment convenience—an often overlooked yet vital aspect for patient quality of life.
Led by Lin Wu, MD, from Hunan Cancer Hospital in Changsha, this trial stands as the first of its kind to evaluate a homegrown anti–PD-1 monoclonal antibody delivered subcutaneously. This is particularly important in China, where immunotherapies are traditionally administered via intravenous routes, leading to lengthy treatment sessions and considerable inconvenience.
This multicenter, open-label phase 3 trial involved adult patients diagnosed with recurrent or metastatic nonsquamous NSCLC without EGFR-sensitive mutations or ALK fusions. Participants were randomly assigned to receive either 360 mg of subcutaneous toripalimab or 240 mg of intravenous toripalimab, each in combination with chemotherapy including pemetrexed and platinum agents. Patients in the subcutaneous group underwent four 21-day treatment cycles and continued maintenance therapy with JS001sc and pemetrexed for up to 35 cycles unless their disease progressed. Both groups followed the same dosing schedule, ensuring a fair comparison.
The trial’s primary endpoints focused on pharmacokinetics—specifically, serum trough concentration at the first cycle and the model-predicted area under the concentration-time curve. Secondary outcomes examined critical clinical factors such as objective response rate, progression-free survival, disease control rate, duration of response, and overall safety.
Candidates for this study had to be at least 18 years old with confirmed nonsquamous NSCLC, no prior systemic therapy for advanced disease, and no presence of EGFR mutations or ALK fusions. They also required measurable cancer lesions according to standard RECIST v1.1 criteria, a good performance status (ECOG 0 or 1), an expected survival of a minimum of 12 weeks, and adequate organ function.
Certain conditions excluded patients from the trial, including the presence of small cell lung cancer components, sarcomatoid lesions, or squamous carcinoma components over 10%. Those with untreated or symptomatic brain metastases, uncontrolled fluid build-ups such as pleural or pericardial effusions requiring frequent drainage, or untreated spinal cord compression were not eligible. Additionally, patients with unresolved toxicities from previous treatments, allergies to study agents, active or past autoimmune diseases, or recent serious infections were also excluded to ensure patient safety.
This development invites us to rethink patient care standards in immuno-oncology. Could shifting from intravenous to subcutaneous delivery become the new norm? And how might this reshape accessibility and patient experience globally? What trade-offs are acceptable when convenience nearly matches but might not fully replicate intravenous efficacy? Readers are encouraged to share their perspectives — do you believe this innovation will set a new standard, or are there hidden pitfalls yet to consider?
References
- Junshi Biosciences announces primary endpoints met in JS001sc’s phase 3 study for the 1st-line treatment of NSQ-NSCLC. News release. Shanghai Junshi Biosciences. November 24, 2025.
- ClinicalTrials.gov: JS001sc or JS001 plus chemotherapy for relapsed or metastatic first-line nonsquamous NSCLC. Updated August 28, 2025.
